2024
Correction: White matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group
Kim B, Kim G, Abe Y, Alonso P, Ameis S, Anticevic A, Arnold P, Balachander S, Banaj N, Bargalló N, Batistuzzo M, Benedetti F, Bertolín S, Beucke J, Bollettini I, Brem S, Brennan B, Buitelaar J, Calvo R, Castelo-Branco M, Cheng Y, Chhatkuli R, Ciullo V, Coelho A, Couto B, Dallaspezia S, Ely B, Ferreira S, Fontaine M, Fouche J, Grazioplene R, Gruner P, Hagen K, Hansen B, Hanna G, Hirano Y, Höxter M, Hough M, Hu H, Huyser C, Ikuta T, Jahanshad N, James A, Jaspers-Fayer F, Kasprzak S, Kathmann N, Kaufmann C, Kim M, Koch K, Kvale G, Kwon J, Lazaro L, Lee J, Lochner C, Lu J, Manrique D, Martínez-Zalacaín I, Masuda Y, Matsumoto K, Maziero M, Menchón J, Minuzzi L, Moreira P, Morgado P, Narayanaswamy J, Narumoto J, Ortiz A, Ota J, Pariente J, Perriello C, Picó-Pérez M, Pittenger C, Poletti S, Real E, Reddy Y, van Rooij D, Sakai Y, Sato J, Segalas C, Shavitt R, Shen Z, Shimizu E, Shivakumar V, Soreni N, Soriano-Mas C, Sousa N, Sousa M, Spalletta G, Stern E, Stewart S, Szeszko P, Thomas R, Thomopoulos S, Vecchio D, Venkatasubramanian G, Vriend C, Walitza S, Wang Z, Watanabe A, Wolters L, Xu J, Yamada K, Yun J, Zarei M, Zhao Q, Zhu X, Thompson P, Bruin W, van Wingen G, Piras F, Piras F, Stein D, van den Heuvel O, Simpson H, Marsh R, Cha J. Correction: White matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group. Molecular Psychiatry 2024, 29: 1216-1216. PMID: 38454086, PMCID: PMC11176053, DOI: 10.1038/s41380-024-02494-9.Peer-Reviewed Original ResearchCorrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.Peer-Reviewed Original ResearchWhite matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group
Kim B, Kim G, Abe Y, Alonso P, Ameis S, Anticevic A, Arnold P, Balachander S, Banaj N, Bargalló N, Batistuzzo M, Benedetti F, Bertolín S, Beucke J, Bollettini I, Brem S, Brennan B, Buitelaar J, Calvo R, Castelo-Branco M, Cheng Y, Chhatkuli R, Ciullo V, Coelho A, Couto B, Dallaspezia S, Ely B, Ferreira S, Fontaine M, Fouche J, Grazioplene R, Gruner P, Hagen K, Hansen B, Hanna G, Hirano Y, Höxter M, Hough M, Hu H, Huyser C, Ikuta T, Jahanshad N, James A, Jaspers-Fayer F, Kasprzak S, Kathmann N, Kaufmann C, Kim M, Koch K, Kvale G, Kwon J, Lazaro L, Lee J, Lochner C, Lu J, Manrique D, Martínez-Zalacaín I, Masuda Y, Matsumoto K, Maziero M, Menchón J, Minuzzi L, Moreira P, Morgado P, Narayanaswamy J, Narumoto J, Ortiz A, Ota J, Pariente J, Perriello C, Picó-Pérez M, Pittenger C, Poletti S, Real E, Reddy Y, van Rooij D, Sakai Y, Sato J, Segalas C, Shavitt R, Shen Z, Shimizu E, Shivakumar V, Soreni N, Soriano-Mas C, Sousa N, Sousa M, Spalletta G, Stern E, Stewart S, Szeszko P, Thomas R, Thomopoulos S, Vecchio D, Venkatasubramanian G, Vriend C, Walitza S, Wang Z, Watanabe A, Wolters L, Xu J, Yamada K, Yun J, Zarei M, Zhao Q, Zhu X, Thompson P, Bruin W, van Wingen G, Piras F, Piras F, Stein D, van den Heuvel O, Simpson H, Marsh R, Cha J. White matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group. Molecular Psychiatry 2024, 29: 1063-1074. PMID: 38326559, PMCID: PMC11176060, DOI: 10.1038/s41380-023-02392-6.Peer-Reviewed Original ResearchObsessive-compulsive disorderNeurobiology of obsessive-compulsive disorderDiffusion tensor imagingENIGMA-OCD working groupClassification of obsessive-compulsive disorderGray matter morphometryWhite matter integrityCross-site generalizabilityHealthy controlsWhite matter pathwaysPosterior thalamic radiationWhite matter featuresMachine learning findingsLeave-one-site-out cross-validationOCD studiesThalamic radiationMedication effectsMultivariate patternsAdult participantsTensor imagingLearning interpretationNeurobiologyCorpus callosumLearning findingsInternal capsuleSafety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary outcomeNon-directive supportClinical effectsTreatment-refractory obsessive-compulsive disorderRefractory obsessive-compulsive disorderSingle-dose trialBlinded ratingsWaitlist-controlled trialDose selection strategiesOCD symptom reductionTreatment of OCDEffects of psilocybinSingle-site trialOCD symptomsInstitutional review boardBlinded independent ratersTrials of psilocybinYale-Brown ObsessiveWaitlist control designPrimary endpointMore dosesFuture trialsSingle dosePsilocybin treatment
2023
The functional connectome in obsessive-compulsive disorder: resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium
Bruin W, Abe Y, Alonso P, Anticevic A, Backhausen L, Balachander S, Bargallo N, Batistuzzo M, Benedetti F, Bertolin Triquell S, Brem S, Calesella F, Couto B, Denys D, Echevarria M, Eng G, Ferreira S, Feusner J, Grazioplene R, Gruner P, Guo J, Hagen K, Hansen B, Hirano Y, Hoexter M, Jahanshad N, Jaspers-Fayer F, Kasprzak S, Kim M, Koch K, Bin Kwak Y, Kwon J, Lazaro L, Li C, Lochner C, Marsh R, Martínez-Zalacaín I, Menchon J, Moreira P, Morgado P, Nakagawa A, Nakao T, Narayanaswamy J, Nurmi E, Zorrilla J, Piacentini J, Picó-Pérez M, Piras F, Piras F, Pittenger C, Reddy J, Rodriguez-Manrique D, Sakai Y, Shimizu E, Shivakumar V, Simpson B, Soriano-Mas C, Sousa N, Spalletta G, Stern E, Evelyn Stewart S, Szeszko P, Tang J, Thomopoulos S, Thorsen A, Yoshida T, Tomiyama H, Vai B, Veer I, Venkatasubramanian G, Vetter N, Vriend C, Walitza S, Waller L, Wang Z, Watanabe A, Wolff N, Yun J, Zhao Q, van Leeuwen W, van Marle H, van de Mortel L, van der Straten A, van der Werf Y, Thompson P, Stein D, van den Heuvel O, van Wingen G. The functional connectome in obsessive-compulsive disorder: resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortium. Molecular Psychiatry 2023, 28: 4307-4319. PMID: 37131072, PMCID: PMC10827654, DOI: 10.1038/s41380-023-02077-0.Peer-Reviewed Original ResearchObsessive-compulsive disorderHealthy controlsFunctional connectivitySensorimotor networkOCD patientsResting-state functional connectivityWhole-brain functional connectivityResting-state connectivityPathophysiological modelPatient statusAccurate biomarkersWidespread abnormalitiesPatientsMajority of studiesEntire brainGeneralizability of resultsGroup differencesFunctional connectomeAbnormalitiesBiomarkersFunctional networksDisordersCurrent knowledgeIndividual levelIndependent samplesSafety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Ching T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary endpointPsilocybin effectsNeural effectsRefractory obsessive-compulsive disorderNon-crossover designOpen-label doseStandard care treatmentOpen-label studyVisual analog scale ratingsTreatment of OCDEffects of psilocybinOCD symptomsInstitutional review boardYale-Brown ObsessivePrimary outcomeSingle doseCare treatmentOral psilocybinInformed consentReview boardNeurobiological mechanismsCompulsive ScalePsychological supportTrials
2022
Obsessive compulsive symptom dimensions are linked to altered white-matter microstructure in a community sample of youth
Grazioplene RG, DeYoung CG, Hampson M, Anticevic A, Pittenger C. Obsessive compulsive symptom dimensions are linked to altered white-matter microstructure in a community sample of youth. Translational Psychiatry 2022, 12: 328. PMID: 35948535, PMCID: PMC9365814, DOI: 10.1038/s41398-022-02013-w.Peer-Reviewed Original ResearchConceptsWhite matter abnormalitiesObsessive-compulsive disorderObsessive-compulsive symptomsGeneral psychopathologyCorpus callosumWhite matterFractional anisotropyDistinct white matter abnormalitiesAnterior corpus callosumPosterior corpus callosumWhite matter correlatesAge-dependent mannerWhite matter measuresGeneral psychopathology factorWhite matter microstructureThe thalamus and its subnuclei—a gateway to obsessive-compulsive disorder
Weeland CJ, Kasprzak S, de Joode NT, Abe Y, Alonso P, Ameis SH, Anticevic A, Arnold PD, Balachander S, Banaj N, Bargallo N, Batistuzzo MC, Benedetti F, Beucke JC, Bollettini I, Brecke V, Brem S, Cappi C, Cheng Y, Cho KIK, Costa DLC, Dallaspezia S, Denys D, Eng GK, Ferreira S, Feusner JD, Fontaine M, Fouche JP, Grazioplene RG, Gruner P, He M, Hirano Y, Hoexter MQ, Huyser C, Hu H, Jaspers-Fayer F, Kathmann N, Kaufmann C, Kim M, Koch K, Bin Kwak Y, Kwon JS, Lazaro L, Li CR, Lochner C, Marsh R, Martínez-Zalacaín I, Mataix-Cols D, Menchón JM, Minnuzi L, Moreira PS, Morgado P, Nakagawa A, Nakamae T, Narayanaswamy JC, Nurmi EL, Ortiz AE, Pariente JC, Piacentini J, Picó-Pérez M, Piras F, Piras F, Pittenger C, Reddy YCJ, Rodriguez-Manrique D, Sakai Y, Shimizu E, Shivakumar V, Simpson HB, Soreni N, Soriano-Mas C, Sousa N, Spalletta G, Stern ER, Stevens MC, Stewart SE, Szeszko PR, Takahashi J, Tanamatis T, Tang J, Thorsen AL, Tolin D, van der Werf YD, van Marle H, van Wingen GA, Vecchio D, Venkatasubramanian G, Walitza S, Wang J, Wang Z, Watanabe A, Wolters LH, Xu X, Yun JY, Zhao Q, White T, Thompson P, Stein D, van den Heuvel O, Vriend C. The thalamus and its subnuclei—a gateway to obsessive-compulsive disorder. Translational Psychiatry 2022, 12: 70. PMID: 35190533, PMCID: PMC8861046, DOI: 10.1038/s41398-022-01823-2.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderMagnetic resonance imagingThalamic volumeOCD patientsThalamic subregionsT1-weighted brain magnetic resonance imagingBrain magnetic resonance imagingClinical-level symptomsLarger thalamic volumesPediatric OCD patientsAdult OCD patientsSeparate multiple linear regression modelsVolumetric group differencesThalamus sizeMedicated patientsAdolescent patientsAnterior thalamusHealthy controlsSubregional volumesGeneral populationMedication statusMultiple comparison correctionPatientsResonance imagingIntracranial volume